Nabi-Hb (Hepatitis B Immune Globulin Drug Interactions
Nabi-Hb (Hepatitis B Immune Globulin (Human)) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Nabi-Hb. Always confirm against the full prescribing information.
100 interactions
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Hepatitis B immune globulin.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hepatitis B immune globulin.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Alirocumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Anthrax immune globulin human.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hepatitis B immune globulin.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Asfotase alfa.
Level 2 evidence
Atezolizumab
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Atezolizumab.
Nabi-Hb (Hepatitis B Immune Globulin (Human)) has 163 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Nabi-Hb (Hepatitis B Immune Globulin (Human)) has 0 major, 1 moderate, and 162 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Nabi-Hb. Always confirm against the full prescribing information.